Newswise — September 14, 2017 – Did you know that routine mammograms can lead to overdiagnosis and overtreatment of breast cancer? Most American women aren't aware of these risks of breast cancer screening, reports a study in the October issue of Medical Care, published by Wolters Kluwer.
What's more, most women don't find statements about breast cancer overdiagnosis and overtreatment to be "believable or persuasive," according to the new research by Rebekah H. Nagler, PhD, of University of Minnesota, Minneapolis, and colleagues. The findings underscore the challenges of accurately communicating these risks so that women can make informed decisions about mammograms and breast cancer screening.
Less Than 20 Percent of US Women Know About Overdiagnosis and Overtreatment
The survey study sought to assess women’s awareness and perceptions of overdiagnosis and overtreatment—two of the main potential harmful effects of breast cancer screening. Overdiagnosis refers to detection of cancers that grow so slowly that they would never have caused any health problems during a woman's lifetime. Overdiagnosis often leads to overtreatment, which refers to unnecessary treatments (such as surgery or medications) that expose women to side effects with minimal health benefits.
"Although it is difficult to pinpoint just how common cancer overdiagnosis is…there is growing expert consensus that the phenomenon is real and may require a re-evaluation of aggressive screening strategies," Dr. Nagler and coauthors write. The authors argue that it is important for patients to understand potential harms such as overdiagnosis and overtreatment so that they can carefully consider whether and when to begin breast cancer screening.
The study was a survey of a nationally representative sample of 429 US women, aged 35 to 55. Only 16.5 percent were aware of the potential risk of overdiagnosis from breast cancer screening, while 18.0 percent were aware of the concept of overtreatment. Women younger than 40 were least likely to have heard about overdiagnosis.
When presented with statements regarding overdiagnosis and overtreatment, most women had negative perceptions. "Fewer than 1 in 4 agreed with and found statements about overdiagnosis and overtreatment to be believable, and even fewer evaluated them as strong arguments to consider in their own mammography decision making," Dr. Nagler and coauthors write.
Women who had recently had a mammogram were "particularly unconvinced" by these statements. Women with a usual source of medical care were also less likely to believe statements regarding overdiagnosis.
Dr. Nagler and colleagues believe their findings have implications for communicating with patients about the potential harms of breast cancer screening. In particular, women with a strong history of following advice to get mammograms might be an important target for interventions to improve informed decision-making.
Given evidence that many women view breast cancer screening favorably, it may be challenging for providers to communicate with patients about its potential harms. Dr. Nagler and coauthors conclude: "Rigorous health communication research is necessary to inform communication interventions that could improve patient understanding of overdiagnosis and overtreatment [and] promote appropriate use of screening."
Article DOI: 10.1097/MLR.0000000000000798
About Medical Care
Rated as one of the top ten journals in health care administration, Medical Care is devoted to all aspects of the administration and delivery of health care. This scholarly journal publishes original, peer-reviewed papers documenting the most current developments in the rapidly changing field of health care. Medical Care provides timely reports on the findings of original investigations into issues related to the research, planning, organization, financing, provision, and evaluation of health services. In addition, numerous special supplementary issues that focus on specialized topics are produced with each volume. Medical Care is the official journal of the Medical Care Section of the American Public Health Association.
About Wolters Kluwer
Wolters Kluwer N.V. (AEX: WKL) is a global leader in information services and solutions for professionals in the health, tax and accounting, risk and compliance, finance and legal sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with specialized technology and services.
Wolters Kluwer reported 2016 annual revenues of €4.3 billion. The company, headquartered in Alphen aan den Rijn, the Netherlands, serves customers in over 180 countries, maintains operations in over 40 countries and employs 19,000 people worldwide.
Wolters Kluwer shares are listed on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY).
Wolters Kluwer Health is a leading global provider of information and point of care solutions for the healthcare industry. For more information about our products and the organization, visit http://www.wolterskluwer.com/, follow @WKHealth or @Wolters_Kluwer on Twitter, like us on Facebook, follow us on LinkedIn, or follow WoltersKluwerComms on YouTube.